Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats

Biopharmaceutics and Drug Disposition

Volumn 36, Issue 1, 2015, Pages 64-68

  Chen, Xinmeng ^a   Jin, Jing ^a   Chen, Yaobin ^a   Peng, Lingling ^a   Zhong, Guoping ^a   Li, Jiali ^a   Bi, Huichang ^a   Cai, Yefeng ^b   Huang, Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Clopidogrel; Metabolism; Pharmacokinetics; Rat microsome; Scutellarin

Indexed keywords

CLOPIDOGREL; SCUTELLARIN; ANTITHROMBOCYTIC AGENT; APIGENIN; GLUCURONIC ACID; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; IC50; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; ERIGERON; HERB DRUG INTERACTION; ISOLATION AND PURIFICATION; LIVER MICROSOME; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; APIGENIN; AREA UNDER CURVE; ERIGERON; GLUCURONATES; HERB-DRUG INTERACTIONS; INHIBITORY CONCENTRATION 50; MALE; MICROSOMES, LIVER; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TICLOPIDINE;

EID: 84921277709     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1918     Document Type: Article

References (17)

1. Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother 2005; 6: 755-764.
2. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-1295.
3. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 2008; 23: 412-420.
4. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
5. Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Design 2006; 12: 1271-1280.
6. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174: 1715-1722.
7. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741.
8. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
9. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-2509.
10. Chen P, Wang DH, Lei WY, Shen ZQ. Effects of scutellarin on thrombosis and platelet aggregation. J KumingMed Coll 2006; 4: 1-5. (In Chinese, abstract in English).
11. Lei KJ, Huang XN, Wu Q, Xie XL, Yu LM, Lu YF. The effects of breviscapine on platelet aggregation and intra-platelet free calcium. Acta Acad Med Zunyi 2004; 27: 11-13. (In Chinese, abstract in English).
12. Yang LM, Gu J, Lin JM, Ge Q, Li LZ. Advances in research on breviscapine. Tianjin Pharmacy 2010; 1: 56-60. (In Chinese, abstract in English).
13. Wang X, Xia H, Liu Y, Qiu F, Di X. Simultaneous determination of three glucuronide conjugates of scutellarein in rat plasma by LC-MS/MS for pharmacokinetic study of breviscapine. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 965C: 79-84.
14. Jian TY, He JC, He GH, et al. Scutellarin inhibits cytochrome P450 isoenzyme 1A2 (CYP1A2) in rats. Phytother Res 2012; 26: 1226-1230.
15. He F, Bi HC, Xie ZY, et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 2007; 21: 635-643.
16. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000; 40: 133-157.
17. Bu HZ, Magis L, Knuth K, Teitelbaum P. Highthroughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001; 15: 741-748.